Current biomarkers such as PD-L1 expression, microsatellite instability (MSI), and tumor mutational burden (TMB) provide some guidance for patient selection but remain insufficiently reliable for accurately identifying individuals most likely to benefit from immunotherapy [103,104,105,106,107]. Here, CD274 is linked to neoplasm.